Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $6.54 for the day, up 2.19% from the previous closing price of $6.4. In other words, the price has increased by $2.19 from its previous closing price. On the day, 37.0 million shares were traded. RXRX stock price reached its highest trading level at $6.56 during the session, while it also had its lowest trading level at $6.0911.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.08.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 27 ’25 when Gibson Christopher sold 138,574 shares for $6.04 per share. The transaction valued at 836,987 led to the insider holds 1,117,450 shares of the business.
Gibson Christopher bought 138,574 shares of RXRX for $836,987 on Mar 27 ’25. On Mar 05 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $6.58 each. As a result, the insider received 131,600 and left with 1,256,024 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2835593472 and an Enterprise Value of 2196722432. For the stock, the TTM Price-to-Sale (P/S) ratio is 47.27 while its Price-to-Book (P/B) ratio in mrq is 2.84. Its current Enterprise Value per Revenue stands at 36.741 whereas that against EBITDA is -4.18.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.92, which has changed by -0.16261202 over the last 52 weeks, in comparison to a change of 0.16260707 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 31.44%, while the 200-Day Moving Average is calculated to be 4.74%.
Shares Statistics:
RXRX traded an average of 26.99M shares per day over the past three months and 36198420 shares per day over the past ten days. A total of 399.15M shares are outstanding, with a floating share count of 330.56M. Insiders hold about 23.50% of the company’s shares, while institutions hold 56.87% stake in the company. Shares short for RXRX as of 1751241600 were 117408745 with a Short Ratio of 4.35, compared to 1748563200 on 109034492. Therefore, it implies a Short% of Shares Outstanding of 117408745 and a Short% of Float of 29.18.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
